AstraZeneca’s Benralizumab Asthma Chase Gets Underway

Watch out GlaxoSmithKline and Teva: AstraZeneca's benralizumab has wind in its sails following a EU CHMP positive opinion for severe asthma. Approval in the US is also expected by year end.

Yacht Race_1200
Benralizumab catches the wind • Source: Shutterstock

AstraZeneca PLC is set to give chase to GlaxoSmithKline PLC's Nucala (mepolizumab) and Teva Pharmaceutical Industries Ltd.'s Cinqair (respizumab) in the severe eosinophilic asthma market, with a positive approval opinion from the European Medicines Agency's CHMP for its monoclonal antibody product benralizumab (as Fasenra) at its latest meeting this week.

More from New Products

More from Scrip